← Leaderboards
Heidi T Jacobe
University Of Pittsburgh At Pittsburgh
$1,705,648
Attributed
$2,848,914
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $581K · FY2008–24$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,848,914 · 4
By mechanism
R01$1,997,383 · 2
K23$562,382 · 1
R56$289,149 · 1
Top collaborators
- Kathryn S. Torok8 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Kathryn S. Torok$2,024,095
- Stephen A Murray$43,730,323
- Elizabeth Jane Leslie-Clarkson$7,303,286
- Richard J Bodnar$119,903
- Parmjeet S Randhawa$5,320,349
Others in their field
Top investigators on “Skin”
- David Heimbrook · Leidos Biomedical Research, Inc.$121,104,269
- Donald Ym Leung · University Of Colorado Denver$58,473,424
- Thomas S. Kupper · Dana-Farber Cancer Institute$53,329,207
- Elaine Fuchs · University Of Chicago$41,573,105
- Timothy Burgess · National Institute Of Allergy And Infectious Diseases$35,600,000
- David Leung · National Jewish Health$31,859,607
Research focus
SkinPrincipal InvestigatorResponseUniversitiesChildhoodAdultMorpheaCohortResearch PersonnelChildMedical CenterFutureResourcesUnited States National Institutes Of HealthImmuneAutoimmune DiseasesInsightSkin TissueInterestSamplingDesignPhenotypeCollaborationsCase Control
Grant awards (13)
Ancillary studies to define dysregulated immune and fibrotic pathways in a well-characterized morphea cohort$296,431
R01 · FY2024 · AR
Ancillary studies to define dysregulated immune and fibrotic pathways in a well-characterized morphea cohort$324,840
R01 · FY2023 · AR
Ancillary studies to define dysregulated immune and fibrotic pathways in a well-characterized morphea cohort$358,735
R01 · FY2022 · AR
Ancillary studies to define dysregulated immune and fibrotic pathways in a well-characterized morphea cohort$376,842
R01 · FY2021 · AR
Refining outcome measures through observational cohorts to advance trials in morphea$204,159
R01 · FY2021 · AR · contact PI
Refining outcome measures through observational cohorts to advance trials in morphea$210,450
R01 · FY2020 · AR · contact PI
Defining dysregulated immune and fibrotic pathways in morphea$289,149
R56 · FY2019 · AR
Refining outcome measures through observational cohorts to advance trials in morphea$225,926
R01 · FY2019 · AR · contact PI
Assessment in Morphea for the Establishment of Non-Cutaneous Disease (AMEND)$115,510
K23 · FY2012 · AR · contact PI
Assessment in Morphea for the Establishment of Non-Cutaneous Disease (AMEND)$115,510
K23 · FY2011 · AR · contact PI
Assessment in Morphea for the Establishment of Non-Cutaneous Disease (AMEND)$112,932
K23 · FY2010 · AR · contact PI
Assessment in Morphea for the Establishment of Non-Cutaneous Disease (AMEND)$110,430
K23 · FY2009 · AR · contact PI
Assessment in Morphea for the Establishment of Non-Cutaneous Disease (AMEND)$108,000
K23 · FY2008 · AR · contact PI